Q1 EPS Estimates for Aclarion Increased by Analyst

Aclarion, Inc. (NASDAQ:ACON) – Investment analysts at Ascendiant Capital Markets boosted their Q1 2026 earnings estimates for shares of Aclarion in a research report issued to clients and investors on Wednesday, March 25th. Ascendiant Capital Markets analyst L. Ward now forecasts that the company will post earnings of ($1.55) per share for the quarter, up from their previous forecast of ($2.79). The consensus estimate for Aclarion’s current full-year earnings is ($263.33) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($1.00) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.37) EPS.

ACON has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. Wall Street Zen upgraded Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aclarion currently has an average rating of “Sell”.

Aclarion Stock Performance

Shares of ACON opened at $3.06 on Monday. Aclarion has a 1 year low of $2.34 and a 1 year high of $15.08. The stock has a 50 day simple moving average of $3.08 and a 200-day simple moving average of $5.50. The stock has a market cap of $6.98 million, a PE ratio of -0.18 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($2.01) EPS for the quarter, topping analysts’ consensus estimates of ($3.60) by $1.59. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Aclarion had a negative net margin of 9,517.11% and a negative return on equity of 52.31%.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.